Greenwoods Asset Management Hong Kong Ltd. Acquires 1,300 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Greenwoods Asset Management Hong Kong Ltd. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,750 shares of the biopharmaceutical company's stock after acquiring an additional 1,300 shares during the quarter. Regeneron Pharmaceuticals accounts for about 0.1% of Greenwoods Asset Management Hong Kong Ltd.'s investment portfolio, making the stock its 27th largest holding. Greenwoods Asset Management Hong Kong Ltd.'s holdings in Regeneron Pharmaceuticals were worth $3,013,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Groupama Asset Managment boosted its holdings in Regeneron Pharmaceuticals by 12.8% in the first quarter. Groupama Asset Managment now owns 90,612 shares of the biopharmaceutical company's stock worth $57,752,000 after purchasing an additional 10,273 shares during the period. Van Lanschot Kempen Investment Management N.V. boosted its holdings in Regeneron Pharmaceuticals by 2.8% in the first quarter. Van Lanschot Kempen Investment Management N.V. now owns 5,467 shares of the biopharmaceutical company's stock worth $3,467,000 after purchasing an additional 149 shares during the period. Legacy Financial Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals by 36.3% in the first quarter. Legacy Financial Advisors Inc. now owns 992 shares of the biopharmaceutical company's stock worth $629,000 after purchasing an additional 264 shares during the period. Colonial Trust Advisors acquired a new position in Regeneron Pharmaceuticals in the first quarter worth $32,000. Finally, Quantbot Technologies LP boosted its holdings in Regeneron Pharmaceuticals by 234.1% in the first quarter. Quantbot Technologies LP now owns 1,764 shares of the biopharmaceutical company's stock worth $1,119,000 after purchasing an additional 1,236 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $8.68 on Friday, reaching $589.48. 1,438,624 shares of the stock traded hands, compared to its average volume of 1,111,801. The firm has a market cap of $62.48 billion, a price-to-earnings ratio of 14.86, a P/E/G ratio of 1.97 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The stock's 50-day moving average price is $549.27 and its 200-day moving average price is $592.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $11.56 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on REGN shares. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a report on Friday, August 1st. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Morgan Stanley restated an "overweight" rating and set a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Finally, Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.